Hua Medicine announced today its third successful clinical trial of lead program HMS5552, a novel glucokinase activator (GKA) treatment for Type 2 diabetes (T2DM).
Continuing its momentum after raising $25 million in Series B financing earlier this year, Hua Medicine, an innovative biotechnology company in Shanghai, has announced the filing of an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA)
Following up on its impressive Phase 1a trial data presented at last year's American Diabetes Association conference, Hua Medicine, an innovative, clinical-stage biotechnology company in Shanghai, announced positive results from its recently completed multicenter, multi-dose Phase 1b Trial in Diabetes.
Hua Medicine Ltd., an innovative, clinical-stage biotechnology company in Shanghai, announced the closing of a $25 million Series B financing.
Hua Medicine Ltd., a leading innovative drug development company in China, announced today the start of multicenter, multi-dose Phase 1b Trials for Diabetes.
Hua Medicine, the leading innovative drug development and commercialization company in China, and Roche announced today a licensing agreement for Roche's Glucokinase Activator (GKA) program.
Copyright © 2019 Hua Medicine, All Rights Reserved沪ICP备14036654号